Surrozen Inc (SRZN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$29.00-8.37%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SRZN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 252.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -82.9% |
Growth built into the price is above our model estimate.
The price assumes 335.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
SRZN — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-10-20
Unregistered Sales of Equity Securities. On October 20, 2026, the Company completed the second tranche closing (the “Second Closing”) under that certain Securities Purchase Agreement, dated March 24, 2025 (the “Purchase Agreement”), with certain institutional and accredited investors (the “Purchasers”) relating to the issuance and sale to the Purchasers of 5,741,605 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), pre-funded warrants (“Pre-Fun…
Why it matters: A study start would move Surrozen's second eye drug into human testing. The company says funding covers its initial development.
Supportive ifSurrozen reports that it has started Phase 1b clinical development of SZN-8143.
Worry ifIn its next business update, the company says SZN-8143 clinical work is delayed, paused, or has not started.
Why it matters: The first study results will show safety and early signs of activity in people with DME.
Supportive ifSurrozen reports early DUET data in the second half of 2027. It shares safety and activity results.
Worry ifThe data arrive after the second half of 2027, or the study stops before results are reported.
Why it matters: Dosing starts the first human test of SZN-8141. A delay would push back the planned study and data.
Supportive ifSurrozen reports that the first patient received SZN-8141 in DUET by December 31, 2026.
Worry ifSurrozen reports no first patient dose by December 31, 2026, or delays the start beyond that date.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$234 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $801 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,265 loss on $10,000 · 52.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.